Norovirus Infection
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
VaxartSOUTH SAN FRANCISCO, CA
2 programsNorwalk GI.1 VirusPHASE_11 trial
VXA-G1.1-NNPHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
VaxartVXA-G1.1-NN
VaxartNorwalk GI.1 Virus
Clinical Trials (2)
Total enrollment: 102 patients across 2 trials
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
Start: Mar 2019Est. completion: Apr 202186 patients
Phase 1Completed
Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model
Start: Oct 2018Est. completion: Nov 201816 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.